Recombinant Anti-Ataxin 1 antibody [EPR19613] - BSA and Azide free (ab225895)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR19613] to Ataxin 1 - BSA and Azide free
- Suitable for: IP, WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Ataxin 1 antibody [EPR19613] - BSA and Azide free
See all Ataxin 1 primary antibodies -
Description
Rabbit monoclonal [EPR19613] to Ataxin 1 - BSA and Azide free -
Host species
Rabbit -
Tested applications
Suitable for: IP, WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: SH-SY5Y, HeLa, U-87 MG, 293T and Neuro-2a whole cell lysates, human cerebellum and fetal brain lysates, 293T transfected with full length human ATXN1 expression vector containing a myc-His-tag® whole cell lysate, HeLa nuclear and membrane fraction lysate. IP: Human brain lysate.
-
General notes
ab225895 is the carrier-free version of ab201037.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Storage buffer
pH: 7.2
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR19613 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab225895 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
Use at an assay dependent concentration.
|
|
WB |
Use at an assay dependent concentration.
|
Notes |
---|
IP
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. |
Target
-
Function
Binds RNA in vitro. May be involved in RNA metabolism. The expansion of the polyglutamine tract may alter this function. -
Tissue specificity
Widely expressed throughout the body. -
Involvement in disease
Defects in ATXN1 are the cause of spinocerebellar ataxia type 1 (SCA1) [MIM:164400]; also known as olivopontocerebellar atrophy I (OPCA I or OPCA1). Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to cerebellum degeneration with variable involvement of the brainstem and spinal cord. SCA1 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. SCA1 is caused by expansion of a CAG repeat in the coding region of ATXN1. Longer expansions result in earlier onset and more severe clinical manifestations of the disease. -
Sequence similarities
Belongs to the ATXN1 family.
Contains 1 AXH domain. -
Domain
The AXH domain is required for interaction with CIC. -
Post-translational
modificationsPhosphorylation at Ser-775 increases the pathogenicity of proteins with an expanded polyglutamine tract.
Sumoylation is dependent on nuclear localization and phosphorylation at Ser-775. It is reduced in the presence of an expanded polyglutamine tract. -
Cellular localization
Cytoplasm. Nucleus. Colocalizes with USP7 in the nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 6310 Human
- Omim: 601556 Human
- SwissProt: P54253 Human
- Unigene: 434961 Human
-
Alternative names
- alternative ataxin1 antibody
- Ataxin-1 antibody
- ATX1 antibody
see all
Images
-
All lanes : Anti-Ataxin 1 antibody [EPR19613] (ab201037) at 1/1000 dilution
Lane 1 : HeLa (Human cervix adenocarcinoma epithelial cell) nuclear fraction lysate
Lane 2 : HeLa (Human cervix adenocarcinoma epithelial cell) membrane fraction lysate
Lane 3 : HeLa (Human cervix adenocarcinoma epithelial cell) cytoplasm fraction lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Exposure time: 60 secondsBlocking buffer and concentration : 5% NFDM/TBST
Diluting buffer and concentration : 5% NFDM /TBSTAtaxin1 is mainly expressed in nuclear (PMID: 23760502, PMID: 9778246, PMID: 21384195 PMID: 32620905).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab201037).
-
Ataxin 1 was immunoprecipitated from 0.35 mg of human brain lysate with ab201037 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab201037 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.
Lane 1: Human brain lysate 10 µg (Input).
Lane 2: ab201037 IP in human brain lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab201037 in human brain lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 1 second.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab201037).
-
All lanes : Anti-Ataxin 1 antibody [EPR19613] (ab201037) at 1/10000 dilution
Lane 1 : 293T (Human embryonic kidney epithelial cell) transfected with an empty vector whole cell lysate
Lane 2 : 293T transfected with full length human ATXN1 expression vector containing a myc-His-tag® whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Exposure time: 1 secondBlocking buffer and concentration : 5% NFDM/TBST
Diluting buffer and concentration : 5% NFDM /TBSTThis data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab201037).
-
All lanes : Anti-Ataxin 1 antibody [EPR19613] (ab201037) at 1/1000 dilution
Lane 1 : SH-SY5Y (human neuroblastoma cell line from bone marrow), whole cell lysate
Lane 2 : HeLa (human epithelial cell line from cervix adenocarcinoma), whole cell lysate
Lane 3 : Neuro-2a (mouse neuroblastoma cell line), whole cell lysate
Lane 4 : Human cerebellum tissue lysate
Lane 5 : Human fetal brain tissue lysate
Lane 6 : U-87 MG (human glioblastoma-astrocytoma epithelial cell line), whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Observed band size: 105 kDa why is the actual band size different from the predicted?Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: Lane 1,2,6: 3 minutes; Lane 3-5: 15 seconds.
The molecular weight observed is consistent with what has been described in the literature (PMID: 7647801).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab201037).
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (0)
ab225895 has not yet been referenced specifically in any publications.